

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

ELITE PHARMACEUTICALS INC /DE/
Form 3
January 16, 2003

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden
hours per response.....0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 3

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(h) of the Investment Company Act of 1940

(Print of Type Responses)

1. Name and Address of Reporting Person*

Sichel Eric L

(Last) (First) (Middle)

411 Highview Road

(Street)

Englewood NJ 07631

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)

August 2, 2001

3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary)

N/A

4. Issuer Name and Ticker or Trading Symbol

Elite Pharmaceuticals, Inc. ELI

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. If Amendment, Date of Original (Month/Day/Year)

Edgar Filing: ELITE PHARMACEUTICALS INC /DE/ - Form 3

7. Individual or Joint/Group Filing (Check Applicable line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I -- Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature (Instr.)
------------------------------------	---	---	-----------------------

N/A

FORM 3 (continued)

Table II -- Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

2. Date Exercisable and Expiration Date	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conve
--	---	----------

